In reference to the growing fears of potential import tariffs within the USA on pharmaceuticals, the generic giant of Indian Dr. Reddy’s laboratories takes steps to secure the supply chain for key products entering the American market, said the overall director of Erez Israeli.
Also read Whether Natco and Dr. Reddy has a duplicate of Ozempicka with slimming ozempic?
“The main problem is the potential disturbance of the supply … Most of the activities we currently perform are closely cooperation with clients and creating appropriate stocks, service, orders and everything that allows us to provide good service,” said Israeli, adding that “the service is our number one priority.”
Israeli spoke on a media briefing on Friday after the corporate published the outcomes of Q4 FY25.
Dr. Reddy has accomplished the sale of a production plant in Shreveport in Louisiana within the quarter of January-Marca FY25. Israeli said that it was not related to tariffs. “The facility could not meet our needs in the field of products and activities not related to tariffs,” he said.
Also read Is Dr. Reddy’s Rose Rose from the expiry of the Revlimid patent?
Israeli said that the drug manufacturer is open to investing in production within the USA, but at this stage he didn’t discover an actual opportunity.
The imposition of US President Donald Trump on import tariffs on key goods emphasizes his program “Made in America”. While pharmaceuticals remain released for now, Trump signaled potential future tariffs, specifically focused on the sector.
“We have a very good balance, we have a very healthy financial capacity. We are always looking for opportunities,” said Israeli in investing within the USA. “We are not in a hurry and we are not obliged to any commitment … But we certainly want to be in the long run of the United States. We will look for the right opportunity for us,” he added.
In Q4 FY25 Dr. Redda’s revenues increased by 20% of the yr ₹8 506 CRRE in comparison with ₹7083 Crore a yr ago, beating estimates. Profits increased by 22% yr on yr to ₹1594 Crore.
Revenues include ₹597 Crore from the acquired consumer healthcare company in nicotine substitute therapy (NRT). Excluding NRT’s activity, the fundamental increase was 12% yr -on -year and a pair of% of the quarter.
Through the complete tax yr FY25, the corporate’s revenues increased by 17% r / ₹32 553 Crore.
Performance results from the contribution acquired activities of NRT, supplemented with constant development in its basic corporations, including global generic and pharmaceutical services in addition to energetic ingredients (PSAI).
Dr. Reddy’s still integrates the NRT portfolio acquired from Haleon PLC in Europe, with Great Britain the primary country to see integration. “In about 12 months we should have most of the countries run by our system or by our distributors. At the same time, we focus on how to develop activities through innovation, by adding countries and improving the activities of this franchise. So in general we are very optimistic about NRT,” said Israeli.
The company goals to introduce 18-20 products within the budget year26. It also increases a biosimilar trace and expects to enter Europe and the USA in the approaching years.
“We are preparing to launch [our] Products in the coming years both in Europe and the USA, “said Israeli. Rituximab, Denosumab and Abatacept will likely be the primary products introduced within the USA, ranging from the tax yr 2027-28
In the budget yr 26, Dr. Reddy hopes to proceed the frenzy through the bottom of the bottom, even when he’s within the face of the lack of exclusivity for the Revlimid anti -cancer drug. Israeli said that other drugs in his pipeline, including GLP-1 and his bios-like, will likely be vital.
